Signaturefd LLC Lowers Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Signaturefd LLC decreased its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 26.2% in the 4th quarter, Holdings Channel reports. The firm owned 677 shares of the biopharmaceutical company’s stock after selling 240 shares during the period. Signaturefd LLC’s holdings in Ultragenyx Pharmaceutical were worth $32,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the business. abrdn plc acquired a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at $6,748,000. Xponance Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 6.8% during the fourth quarter. Xponance Inc. now owns 10,162 shares of the biopharmaceutical company’s stock worth $486,000 after buying an additional 648 shares during the last quarter. Federated Hermes Inc. increased its position in Ultragenyx Pharmaceutical by 11.4% in the 4th quarter. Federated Hermes Inc. now owns 2,446,500 shares of the biopharmaceutical company’s stock valued at $116,992,000 after acquiring an additional 250,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Ultragenyx Pharmaceutical by 14.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,147 shares of the biopharmaceutical company’s stock valued at $772,000 after acquiring an additional 2,011 shares during the period. Finally, Cornercap Investment Counsel Inc. purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter valued at approximately $246,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 1.0 %

Shares of Ultragenyx Pharmaceutical stock opened at $42.75 on Friday. The company has a 50-day moving average of $47.25 and a two-hundred day moving average of $44.08. The stock has a market cap of $3.55 billion, a PE ratio of -5.13 and a beta of 0.68. Ultragenyx Pharmaceutical Inc. has a 12-month low of $31.52 and a 12-month high of $54.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by ($0.31). The firm had revenue of $108.83 million for the quarter, compared to analyst estimates of $116.03 million. Ultragenyx Pharmaceutical had a negative return on equity of 369.54% and a negative net margin of 139.70%. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.33) earnings per share. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RARE has been the topic of several analyst reports. Royal Bank of Canada assumed coverage on Ultragenyx Pharmaceutical in a research note on Monday, April 22nd. They issued an “outperform” rating and a $77.00 target price on the stock. Wedbush lowered their price objective on shares of Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday. JPMorgan Chase & Co. upped their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. TD Cowen raised their target price on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $88.00.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, EVP Thomas Richard Kassberg sold 11,509 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $49.93, for a total value of $574,644.37. Following the sale, the executive vice president now directly owns 252,823 shares of the company’s stock, valued at approximately $12,623,452.39. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, EVP Thomas Richard Kassberg sold 11,509 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $49.93, for a total transaction of $574,644.37. Following the transaction, the executive vice president now directly owns 252,823 shares in the company, valued at $12,623,452.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John Richard Pinion sold 4,173 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $224,340.48. Following the completion of the sale, the insider now owns 89,268 shares of the company’s stock, valued at approximately $4,799,047.68. The disclosure for this sale can be found here. Insiders sold 32,116 shares of company stock valued at $1,645,983 in the last 90 days. 6.80% of the stock is currently owned by insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.